Research Grants
Exploring the TNFRSF14 locus in Follicular Lymphoma
Role Involved : Principal Investigator
Other Investigators: Douglas Stewart, Etienne Mahe, Ariz Akhter
(Co-I’s)
Agencies : Alberta Precision Labs
Total Award : $6,000.00 (2021)
Pan Canadian harmonization of Immunohistochemistry
protocols for cell of origin classification of diffuse large B-cell lymphoma (DLBCL)
Role Involved : Co- Principal Investigator
Other Investigators : Emina E. Torlakovic (Co-PI)
Agencies : Jensen Canada/ Johnson & Johnson Research Fund
Total Award : $56,430 (2017 – 2020))
Prognostic biomarkers through gene expression in non-Hodgkin
lymphoma such primary CNS and Testicular lymphoma arising at Immune
privileged sites
Role Involved : Co- Principal Investigator
Other Investigators : Carolyn Owen (Co-PI), Stewart D (Co-PI);
Agencies : Calgary Health Trust Hematology Education and Research Fund
Total Award : $65,000 (2016 - 2017)
Prediction of prognosis in myeloid neoplasms
Prediction of prognosis in myeloid neoplasms through next generation
sequencing platform; validation of myeloid panel.
Role Involved : Co- Investigator
Other Investigators : Faisal Khan (Co-PI), Meer-Taher Shabani-Rad (Co-PI);
Agencies : Calgary Health Trust Hematology Education and Research Fund
Total Award : $85,000 (2016 - 2017)
Development of a Tissue-based & Cell-Free
DNA (cfDNA) Next-Generation
Sequencing (NGS) Workflow
Role Involved : Co-Investigator
Other Investigators : Etienne Mahe (PI), Meer-Taher Shabani-Rad (Co-Inv)
Agency : Calgary Laboratory Services (CLS) Research Fund
Total Award : $45,000.00 (2016 – 2018)
Prognostic Significance of MN1, ERG, BAALC and EVI1 (MEBE) Expression
Signature in Various Cytogenetic Risk Groups Among Patients with Acute Myeloid
Leukemia
Role Involved : Principal Investigator
Other Investigators : Ariz Akhter (Co-PI), Meer-Taher Shabani-Rad, Fariborz Kolvear
Agency : Calgary Laboratory Services (CLS) Research Fund
Total Award : $9,853.00 (2015 – 2017)
Role of Natural Killer Cells Receptor genes
Role of Natural Killer Cells Receptor genes in the immunopathogenesis
and prognosis of different types of Lymphoma.
Role Involved : Co-Investigator
Other Investigators: Faisal Khan (PI), Douglas Stewart
Agency : Alberta Cancer Foundation
Total Award : $97,125 (2015-2018)
Validation of “nCounter Leukemia Fusion Gene
Expression AssayKit” by
Nanostring technologies to determine multiple genetic aberrations for
classification of Acute Leukemia.
Role Involved: Co-Principal-Investigator
Other Investigators: Meer-Taher Shabani-Rad (co-PI); Fahad Farooq
Agency: Calgary Laboratory Services (CLS) Research Fund
Total Award : $9,800 (2014 - 2016)
Predict Benefit and Improve Outcomes of Conventional High Dose
Therapy/Stem Cell Transplantation for Lymphoma Patients through Molecular
Biomarkers
Role Involved :Co-PrincipalInvestigator
OtherInvestigators : StewartD(Co-PI);Owen C (Co-PI)
Agencies : Alberta Cancer Foundation (ACF) /Stephure Directed Donation
Total Award : $200,000 (2014 - 2016)
Follicular lymphoma: Identifying a “Proliferative Molecular Signature”
: Follicular lymphoma: Identifying a “Proliferative Molecular Signature” as
a predictor of aggressive clinical disease and its validation through routine
immunohistochemistry techniques
Role Involved : Co- Principal Investigator
Other Investigators : Stewart D (Co-PI), Mahe E, Danielle Oh, Akhter A
Agencies : Calgary Health Trust Hematology Education and Research Fund
Total Award : $15,000 (2014 - 2016)
“Metabolomics Profiling of Follicular Lymphoma"
Role Involved : Co-Investigator
Other Investigators : Stewart D (PI), Meer-Taher Shabani-Rad,
Agencies : Calgary Health Trust / Hematology Education and Research Fund
Total Award : $15,000 (2014 - 2016)
Reovirus as a viable therapeutic
Reovirus as a viable therapeutic option to target therapy resistance of
multiple myeloma
Role Involved : Co-Investigator
Other Investigators : Morris, D (PI), Thirukkumaran C
Agencies : Cancer Research Society
Total Award : $120,000 (2013 - 2015)
Hematological profile, appropriate for gestational
Hematological profile, appropriate for gestational age infants born to
mothers with early onset preeclampsia
Role involved : Co-investigator
Other Investigators : Kamran Yusuf (PI)
Agencies : Alberta Children’s Hospital Research Institute (ACHRI)
Total Award : $2,985 (2013 - 2014)
Toward improved outcomes of antithymocyte
Toward improved outcomes of antithymocyte globulin-conditioned
hematopoietic cell transplantation
Role Involved : Collaborator
Other Investigators : Storek J (PI) , Khan F, Morris D, Daly A, Larratt L, Preiksaitis J,
Agencies : Alberta Innovates – Health Solutions (AIHS)- CRIO grant
Total Award : $750,000 (2011 - 2013)
Predicting benefit of standard treatment and personalize
Predicting benefit of standard treatment and personalize medicine for
relapse/refractory diffuse large B-cell lymphoma using genetic and proteomic testing
Role Involved :Co-Principal Investigator
Other Investigators :StewartD(Co-PI),Bosch,M
Agencies : Calgary Health Trust / Hematology Education and Research Fund
Total Award : $40,000 (2012 - 2013)
Creation of a Lymphoma Tissue Bank
Creation of a Lymphoma Tissue Bank through Establishing a Cancer
Research Fellowship
Role Involved :Co-PrincipalInvestigator Other Investigators: Stewart D (Co-PI),
Agencies : Alberta Cancer Foundation / Stephure Directed Donation
Total Award:: $250,000 (2012 - 2014)
Predicting benefit of salvage and high dose chemotherapy with autologous
stem cell transplantation for relapsed Diffuse Large B-cell Lymphoma patients
through tissue array based biomarker classifications.
Role Involved : Co-Principal Investigator
Other Investigators : Stewart D (Co-PI), Mark Bosch
Agencies : Alberta Cancer Foundation/ Directed Donation
Total Award : $41,302 (2011 - 2012)
Expression of CD-20-related genes in Lymphocytic Neoplasm
Role Involved : Co-investigator
Other Investigators : Julie Deans (PI), Iwona Auer, Doug Stewart, Doug Demetrick
Agencies : CIHR
Total Award : $152,875 (2008 - 2011)
Prediction of outcomes of HCT using novel immune assays
Role Involved : Co-investigator
Other Investigator : Storek J (PI)
Agencies : ACRI Operating Grant
Total Award : $452,633 (2008 - 2009)
Therapeutic Targets and Prognostic Markers for Mantle cell lymphoma
Role Involved : Co-investigator
Other Investigator : Dr. Lai R (PI), Stewart D Agencies: CIHR
Total Award : $330,000 (2008-2011)
Tissue-Based Array Classification of Multiple Myeloma.
Role Involved : Collaborator
Other Investigator : Klimowicz A, Bahlis N (PI)
Agencies : Multiple Myeloma Research Foundation
Total Award : $75,000 (2008 – 2009)
Predicting benefit and improving outcomes of high dose therapy (HDT)
Predicting benefit and improving outcomes of high dose therapy (HDT)
and autologous stem cell transplantation for myeloma patients through tissue
arrays based classification.
Role Involved :Co-Principal Investigator
Other Investigator : StewartD(Co-PI); BahlisN(Co-PI)
Agencies : Terry Fox Research Institute and Alberta Cancer Foundation
Total Award : $1,315,107 (2008 - 2011)
An “observer-independent” and fully quantitative Tissue Microarray
An “observer-independent” and fully quantitative Tissue Microarray
(TMA) based classification is predictive of survival among Multiple Myeloma
(MM) patients
Role Involved :Co-Principal Investigator
OtherInvestigator : StewartD;BahlisN(Co-PI)
Agencies :Calgary Laboratory Services
Total Award : $9,950 (2008 – 2011)
Tissue Based Array Classification of Multiple Myeloma
Role Involved : Collaborator
Other Investigator : Stewart D; Bahlis N (PI)
Agencies : Alberta Cancer Board Research
Funding Committee (ACB-RFC)
Total Award : $35,000 (2007
Validation of interphase FISH (Fluorescent in-Situ Hybridization)
Validation of interphase FISH (Fluorescent in-Situ Hybridization) and
immunohistochemical staining as prognostic tools in Multiple Myeloma
patients undergoing autologous stem cell transplantation
Role Involved : Co-Principal Investigator
Other Investigator : Stewart D; Bahlis N (Co-PI)
Agencies : Calgary Laboratory Services
Total Award : $7,500 (2007 - 2009)
Weight-Adjusted Dosing of Tinzaparin in Pregnancy
Role Involved : Co-Investigator
Other Investigator : Gibson, P (PI)
Agencies : Leo Pharma
Total Award : $29,000 (2007 - 2009).
Tissue and RT-PCR-based Classification of Multiple Myeloma
Role Involved : Co-investigator
Other Investigator : Stewart D; Bahlis N (PI)
Agencies : Research/Education Fund – Div. of Hematology, University ofCalgary,
Total Award : $32,000 (2006 - 2007).
Detection of CD25 as a Surrogate Marker for Prognosis
Detection of CD25 as a Surrogate Marker for Prognosis of Patients with
Mutated or Unmutated B-Cell Chronic Lymphocytic Leukemia (CLL)
Role Involved : Co-Principal Investigator
Other Investigator: Howell, J (Co-PI)
Agencies : Leukemia and Lymphoma Society of Canada
Total Award : $5,000 (2006)
Frontline: Evaluation of predictive markers
Frontline: Evaluation of predictive markers among aggressive Non-Hodgkin Lymphomas treated with Double High Dose Chemother
Role involved : Co-Principal Investigator
Other Investigators : StewartD(Co-PI)
Funded : Research / Education Fund – Division of Hematology, University of
Calgary,
Total Award : $10,000 (2005 – 2006)
Validating p-PKCd, p-AKT and PTEN as Prognostic Markers in Multiple Myeloma.
Role Involved : Co-Principal Investigator
Other Investigator : StewartD;BahlisN(Co-PI)
Agencies : Calgary LaboratoryServices
Total Award : $7,360 (2004 -2007).
Expression of TIMP-1 and STAT3 in Diffuse Large B-cell Lymphomas.
Role involved : Principal Investigator
Other Investigator : Stewart D; Bahlis N
Agencies : Calgary Laboratory ServicesTotal
Award : $6,500 (2003 - 2006).
Comparison of PT/INR values by Point-of-Care (Coagu-check) and MLA-1800 methods, among Acute Stroke patients.
Role involved : Co-Investigator
Other Investigator : Lyon, M (PI)
Agencies : Calgary Laboratory Services Total
Award : $5,500 (2004 - 2006)
